Will another ADC breast cancer drug, ‘Troldelvy,’ follow the footsteps of ‘Enhertu’?

According to industry sources, Gilead Sciences Korea's triple-negative breast cancer (TNBC) drug Troldelvy (sacituzumab govitecan-hziy), which passed the Health Insurance Review and Assessment Service's Cancer Disease Review Committee in November last year, is yet to be presented from the Drug Reimbursement Evaluation Committee for review. Therefore, whether the agenda will be discussed at the upcoming DREC meeting is gaining attention.

Trodelvy is an antibody-drug conjugate (ADC) that consists of a monoclonal antibody that binds to the cell surface antigen Trop-2 and ‘SN-38,’ a TOP1 inhibi